Fig. 4: BAP1 knockdown conferred cellular resistance to BET inhibitor JQ1 and Aurora kinase inhibitor Alisertib in NB. | Cell Death & Disease

Fig. 4: BAP1 knockdown conferred cellular resistance to BET inhibitor JQ1 and Aurora kinase inhibitor Alisertib in NB.

From: Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN

Fig. 4

A, B Cell viability of BE2C cells with shRNA-mediated BAP1 knockdown (shBAP1) that were treated with indicated concentration of JQ1 (A) and Alisertib (B) for 24 h. shScr BE2C cells were used as control. P values are shown in figure, t test. C, D Representative images for the wound-healing assays of BAP1-knockdown (shBAP1) BE2C cells with or without JQ1 (C) and Alisertib (D) treatment. The wound edges are indicated by yellow lines. Scale bar, 100 μm. E The quantitative results of (C, D) (n = 8). The y axis represents the relative wound area. Error bars represent SD from eight repeats. t test. F, G Colony-formation assay. knockdown of endogenous BAP1 in BE2C cells displays moderate resistance to JQ1 and Alisertib treatment in colony-formation ability. The number of colonies were counted and quantified. The colony number of shScr and shBAP1 without drug treatment groups are set up to “100%”, then the colony number of the drug treatment groups were compared with the relative colony number of shScr and/or shBAP1. Data are shown as mean ± SD for three independent experiments. *P < 0.05, t test. BE2C cells were infected with indicated lentiviral shRNAs. The infected cells were selected with 2 μg/ml puromycin for 72 h to eliminate non-infected cells before they were used for colony-formation assay. H, I Cell viability of BE2C cells with shRNA-mediated BAP1 knockdown (shBAP1) and stably expressing MYCN that were treated with the indicated concentration of JQ1 (H) and Alisertib (I) for 48 h. shScr BE2C cells were used as control. *P < 0.05, **P < 0.01, t test. J, K Growth curves of BE2C cells with shRNA-mediated BAP1 knockdown (shBAP1) and stably expressing MYCN that were treated with or without 0.5 μM JQ1 (J) and 0.2 μM Alisertib (K) for 6 days. shScr BE2C cells were used as control. **P < 0.01, t test.

Back to article page